This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
This is a multi-center, non-randomized, single-arm, open-label, phase Ib dose escalation/dose expansion study of PTM-101 in subjects with pancreatic ductal adenocarcinoma (PDAC). Dose escalation will assess the safety of PTM-101 containing escalating doses of paclitaxel to establish the preliminary Recommended Phase II Dose (RP2D) when combined with neoadjuvant chemotherapy for subjects who are treatment-naïve, have borderline resectable or locally advanced PDAC and are eligible for neoadjuvant chemotherapy. Subsequently, the dose expansion portion will expand the number of subjects at the preliminary RP2D to assess the efficacy of PTM-101.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
26
PTM-101, an absorbable drug product containing paclitaxel
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
RECRUITINGKarmanos Cancer Institute
Detroit, Michigan, United States
RECRUITINGNorthwell Health Zuckerberg Cancer Center
Lake Success, New York, United States
Dose Escalation
Number of subjects with PTM-101/PTM-101 placement-related adverse events as assessed by CTCAE v5.0
Time frame: Within 21 days of PTM-101 placement
Dose Expansion
Safety: serious adverse events related to PTM-101 or PTM-101 placement
Time frame: Within 3 months of PTM-101 placement
Dose Expansion
Efficacy: volume response rate (VRR) of ≥ 40% reduction in tumor volume
Time frame: Within 3 months of PTM-101 placement
Dose Escalation and Dose Expansion
Overall response rate (ORR) by RECIST 1.1 and WHO
Time frame: At 21 days and 3 months post PTM-101 placement
Dose Escalation and Dose Expansion
Progression free survival (PFS) per RECIST 1.1
Time frame: Within 24 months of PTM-101 placement
Dose Escalation and Dose Expansion
Overall survival (OS)
Time frame: Within 24 months of PTM-101 placement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Texas Southwestern Medical Center
Dallas, Texas, United States
NOT_YET_RECRUITINGThe University of Texas MD Anderson Cancer Center
Houston, Texas, United States
RECRUITINGVirginia Mason Medical Center
Seattle, Washington, United States
RECRUITING